ViroGates lists on Nasdaq First North in Denmark and raises new capital for commercialization

ViroGates was listed on Nasdaq First North in Denmark on 26 June 2018 and in raised in that connection gross proceeds of DKK 75 million to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage. ViroGates is a medical technology company that develops and markets prognostic products for the healthcare sector. ViroGates’ suPARnostic® products are used by emergency department staff to quickly assess if patients should be admitted or discharged, and products are furthermore used for prognostication of cardiovascular diseases, type-2 diabetes, cancer, among other things.

We have initiated our commercial roll-out in Europe, and hospitals in several countries are testing our product in their daily routines of deciding whether to admit or discharge patients from emergency departments. We want to significantly accelerate the commercialization pace, and our objectives are to have 40 hospitals as paying customers and to become cash flow positive by the end of 2020," Jakob Knudsen, CEO

Do you want to know more?

Prospectus

Read the prospectus in English with description of our business, markets, strategy, objectives, management, risks, etc.

 

Swedish prospectus summary

Read a Swedish summary of the prospectus as published on 4 June 2018.

 

Prospectus announcement

Read the English prospectus announcement as published on 4 June 2018.

 

Brochure

Read a brief description in Swedish of ViroGates and the offering.

 

 This is what we will use the proceeds for

The offering has secured gross proceeds of DKK 75.0 million, which is expected to primarily be used for:

    • 60-70% for commercial execution, i.e. building a sales organization in the European markets where regulatory approval has been established for the suPARnostic® products, as well as establishing commercial partnerships in selected markets
    • 10-20% to secure necessary product development
    • 5-10% to generate additional clinical documentation
    • 5-10% to secure the global coverage of the most recently filed patent on the use of suPARnostic® in emergency departments

Meet our CEO

We hosted a number of meetings during the subscription period where CEO Jakob Knudsen presented the initial public offering and our plans.

    • 11 June: Aktiespararnas Småbolagsdag in Stockholm - see the presentation here
    • 12 June: InvestorDagen in Aarhus in cooperation with Danish Shareholders’ Association - see presentation here (in Danish)
    • 14 June: Meeting in Copenhagen in cooperation with Nordnet.
    • 18 June: Meeting at Schæffergaarden in Gentofte at 5:00-7:00 p.m. CET in cooperation with Danish Shareholders’ Association